

***Trypanosoma cruzi*, Strain VL2067, Clone A8 (+lacZ)**

**Catalog No. NR-18962**

**For research use only. Not for human use.**

**Contributor:**

F. S. Buckner, Associate Professor, Department of Medicine, University of Washington, Seattle, Washington, U. S. A.

**Manufacturer:**

BEI Resources

**Product Description:**

Protozoa Classification: *Trypanosomatidae*, *Trypanosoma*

Species: *Trypanosoma cruzi*

Strain: VL2067 (clone A8; +lacZ)

Original Source: *Trypanosoma cruzi* (*T. cruzi*), strain VL2067, clone A8 (+lacZ) is a transgenic clone derived from the pathogenic VL2067 strain.<sup>1</sup> Strain VL2067 was originally isolated in Minas Gerais, Brazil.<sup>2</sup>

Comment: *T. cruzi*, strain VL2067, clone A8 (+lacZ) was deposited to BEI Resources as a  $\beta$ -galactosidase-expressing strain consisting of the trypomastigote stage of the parasite's life cycle.

The protozoan parasite *T. cruzi* is the causative agent of Chagas' disease, a debilitating disease endemic in many Latin American countries. The search for trypanosomicidal compounds can be facilitated by utilization of a colorimetric reaction to quantitate parasitic growth in tissue culture cells (modeling an *in vivo* infection). *T. cruzi*, strain VL2067, clone A8 (+lacZ) has been genetically engineered to express *Escherichia coli*  $\beta$ -galactosidase (*lacZ*) an enzyme that can catalyze a colorimetric reaction with chlorophenol red  $\beta$ -D-galactopyranoside (CPRG).<sup>1,3</sup> The amount of enzymatic activity is directly proportional to the number of transfected parasites making this activity easily and accurately measured on a 96-well tissue culture plate using a microplate reader.<sup>1</sup> The utilization of the  $\beta$ -galactosidase-expressing parasites facilitates high throughput screening of large numbers of candidate compounds against *T. cruzi*.<sup>1</sup>

**Material Provided:**

Each vial of NR-18962 contains approximately 0.5 mL of culture in cryopreservative. Please see Appendix I for cryopreservation instructions.

**Packaging/Storage:**

NR-18962 was packaged aseptically in screw-capped plastic cryovials and is provided frozen on dry ice. The product should be stored at cryogenic temperature (-130°C or colder), preferably in the vapor phase of a liquid nitrogen freezer. If liquid nitrogen storage facilities are not available, frozen cryovials may be stored at -70°C or colder for approximately one week. Note: Do not under any

circumstances store vials at temperatures warmer than -70°C. Storage under these conditions will result in the death of the culture.

To insure the highest level of viability, the culture should be initiated immediately upon receipt. Any warming of the product during shipping and transfer must be avoided, as this will adversely affect the viability of the product. For transfer between freezers and for shipping, the product may be placed on dry ice for brief periods, although use of a portable liquid nitrogen carrier is preferred. Please read the following recommendations prior to using this material.

**Growth Conditions:**

ATCC® medium 2222: Cell cultivation medium for parasites (Dulbecco's Minimal Essential Medium), adjusted to contain 10% (v/v) heat-inactivated fetal bovine serum (HIFBS)

BALB/3T3 clone A31 mouse embryonic fibroblasts (ATCC® CCL-163™)

Incubation:

Temperature: 35°C to 37°C

Atmosphere: 95% air, 5% CO<sub>2</sub>

Propagation:

1. To establish a culture from the frozen state, place a vial in a 35°C to 37°C water bath. Thawing time is approximately 2 to 3 minutes. Do not agitate the vial. Do not leave the vial in the water bath after it is thawed.
2. Immediately after thawing, aseptically transfer the contents to a tissue culture flask containing a fresh monolayer of BALB/3T3 clone A31 mouse embryonic fibroblasts (ATCC® CCL-163™) and 10 mL of ATCC® medium 2222 containing 10% (v/v) HIFBS.
3. Outgas the flask for 10 seconds with a 95% air, 5% CO<sub>2</sub> gas mixture.
4. Incubate in a 35°C to 37°C CO<sub>2</sub> incubator with the caps screwed on tightly. Observe the culture daily under an inverted microscope for the presence of intracellular forms of the parasite. The emergence of trypomastigotes from host cells is usually observed between 5 to 7 days.

Maintenance:

1. Remove the medium from a fresh confluent monolayer of BALB/3T3 clone A31 mouse embryonic fibroblasts in a tissue culture flask and replace it with 10 mL medium containing 10% (v/v) HIFBS.
2. Remove the medium containing the trypomastigotes from the *Trypanosoma* culture and transfer to a 15 mL centrifuge tube. Centrifuge the parasites at 1300 x g for 10 minutes.
3. Remove the supernatant and resuspend the cell pellet in a small volume (0.5 to 1.0 mL) of ATCC® medium 2222. Transfer the resuspended pellet to the fresh flask of BALB/3T3 clone A31 mouse embryonic fibroblasts, prepared in step 1 above. Follow steps 3 and 4 in Propagation.

**Citation:**

Acknowledgment for publications should read “The following reagent was obtained through the BEI Resources, NIAID, NIH: *Trypanosoma cruzi*, Strain VL2067, Clone A8 (+lacZ), NR-18962.”

**Biosafety Level: 2**

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see [www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm](http://www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm).

**Disclaimers:**

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

**Use Restrictions:**

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

**References:**

1. Buckner, F. S., et al. “Efficient Technique for Screening Drugs for Activity against *Trypanosoma cruzi* using Parasites Expressing  $\beta$ -Galactosidase.” Antimicrob. Agents Chemother. 40 (1996): 2592-2597. PubMed: 8913471.

2. Buckner, F. S., et al. “Potent Anti-*Trypanosoma cruzi* Activities of Oxidosqualene Cyclase Inhibitors.” Antimicrob. Agents Chemother. 45 (2001): 1210-1215. PubMed: 11257036.
3. Buckner, F. S., A. J. Wilson and W. C. Van Voorhis. “Detection of Live *Trypanosoma cruzi* in Tissues of Infected Mice by using Histochemical Stain for  $\beta$ -Galactosidase.” Infect. Immun. 67 (1999): 403-409. PubMed: 9864242.

ATCC® is a trademark of the American Type Culture Collection.



**APPENDIX I: CRYOPRESERVATION**

1. To harvest *Trypanosoma cruzi*, remove the media containing trypomastigotes from a series of infected cultures in T75 flasks and transfer to 15 mL plastic centrifuge tubes. Centrifuge at 1300 x g for 10 min.
2. Remove all but 0.5 mL of the supernatant from each tube, resuspend the cell pellets, and pool them to a single tube.
3. Adjust the parasite concentration to 2.0 to 4.0 x 10<sup>7</sup> cells/mL using fresh growth medium [Cell cultivation medium for parasites (ATCC® medium 2222)]. Note: If the concentration of parasites is too low, centrifuge at 1300 x g for 10 min and resuspend in a smaller volume of fresh medium to yield the desired parasite concentration.
4. Mix equal volumes of parasite suspension and fresh medium containing 10% DMSO to yield a final concentration of 1.0 to 2.0 x 10<sup>7</sup> cells/mL in 5% DMSO. The freezing process should start 15 to 30 minutes following the addition of cryoprotective solution to the parasite suspension. Note: To prevent culture contamination, penicillin-streptomycin solution (ATCC® 30-2300) may be added to a final concentration of 50 to 100 U/mL penicillin and 50 to 100 µg/mL streptomycin.
5. Dispense 0.5 mL aliquots into 1 to 2 mL sterile plastic screw-capped vials for cryopreservation.
6. Place the vials in a controlled rate freezing unit. From room temperature cool the vials at -1°C/min to -40°C. If the freezing unit can compensate for the heat of fusion, maintain rate at -1°C/min through this phase. At -40°C, plunge vials into liquid nitrogen. Alternatively, place the vials in a Nalgene 1°C freezing container. Place the container at -80°C for 1.5 to 2 hours and then plunge vials into liquid nitrogen.
7. Store in either the vapor or liquid phase of a nitrogen refrigerator (-130°C or colder).